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July 26, 2011:548–51heart rates. Bazett’s formula will greatly overcorrect the QT interval at
any heart rate60 beats/min, and attempts should always be made to
record an electrocardiogram as close to 60 beats/min as possible by
obtaining data from Holter monitoring or using a beta-blocker.
There is no doubt about the potential arrhythmic risk of a short
QT interval, but corrected QT intervals as low as 340 to 350 ms
(considered normal by some) have been observed for years without
reports of any increased risk for sudden cardiac death. So far, SQTS
has been an extremely rare diagnosis, with no documentation of
sudden cardiac death or aborted sudden cardiac death due to SQTS
when the QT interval is 315 ms.
Therefore, it is my opinion that the proposed diagnostic criteria for
SQTS are poorly founded and should be used with great caution.
*Preben Bjerregaard, MD, DMSc
*Department of Cardiology
St. Louis VA Medical Center
915 North Grand Boulevard
St. Louis, Missouri 63106
E-mail: preben.bjerregaard@va.gov
doi:10.1016/j.jacc.2011.03.037
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Reply
Dr. Bjerregaard challenges the inclusion of 5 of 61 patients used in
our analysis of reported cases of short-QT syndrome (SQTS) (1). We
commend him on the considerable amount of time spent reviewing
these cases and focusing on the relevance of their inclusion. Dr.
Bjerregaard suggests that cases 23 and 49 are the same patient and
that we have reported the patient twice but with “different ages and
QT intervals.” His rationale for arriving at this conclusion is unclear.
These patients are reported from different published reports, without
any indication of having been previously described, and their differing
QT intervals reflect the values quoted directly from these reports.
With regard to patient #46, Dr. Bjerregaard is concerned about the
terminology used in describing this patient’s clinical event and the fact
that his mother carries the same KCNH2 gene mutation (E50D)
despite having a normal corrected (QTc) interval. This patient (QTc
intervals ranging from 349 to 381 ms) had a sudden loss of conscious-
ness in the absence of a prodrome, resulting in a motor vehicle
accident. After cardiac evaluation, clinically his event was attributed to
a sudden arrhythmia with spontaneous reversion, consistent with the
concept of an aborted cardiac arrest. Dr. Bjerregaard’s concern
regarding a gene carrier demonstrating a normal phenotype is quite
surprising, as this is a common observation in virtually all inherited
arrhythmia conditions. The E50D mutation has never previously
been observed and was absent from the screening of more than 2,600
chromosomes analyzed in a healthy control cohort (2). In collabora-
ion with Dr. Charles Antzelevitch, biophysical analysis of this
utation confirmed a significant gain of function consistent with
revious mutations reported in patients with SQTS.The remaining 3 patients (patients #59 to #61) of concern to Dr.
jerregaard were reported to have a novel KCNH2 gene mutation
R1135H). Biophysical studies demonstrated a significant gain of
unction of the mutant protein consistent with the SQTS phenotype
n these 3 patients (3). One of these patients was also reported to have
“Brugada-type” electrocardiographic (ECG) pattern, although the
2-lead electrocardiogram was not published. Our view is that it is
xtremely unlikely that this patient had a type 1 Brugada ECG
attern, required to conclude a Brugada phenotype, and that the
bserved Brugada-type ECG pattern more likely reflected the non-
pecific type 2 or 3 pattern. The KCNH2 gene, which has been the
ubject of analysis in inherited arrhythmias for more than 15 years, has
ever been associated with a type 1 Brugada ECG pattern.
More relevant to the challenge of diagnosing the SQTS is the issue
f QTc ranges that may be associated with the condition. Dr.
jerregaard suggests that QT interval correction should be avoided
nd that instead, analysis of the absolute QT interval should be
estricted to periods when the heart rate approximates 60 beats/min,
nd he suggests that Holter monitoring would be useful. We do not
elieve that this approach is feasible in clinical practice and do not
dvocate using Holter monitors for the evaluation of QT intervals. All
urrently reported SQTS cases have reported the QTc interval, and
lthough the use of the Bazett correction formula has certain limita-
ions, these limitations are minimized when appropriate reference
anges of “normal” are considered. As described in our report,
umerous large epidemiologic studies have reported the QTc interval
ange in thousands of subjects, providing a useful resource of the
ormal distribution of QTc intervals on resting 12-lead electrocardi-
graphy in the general population.
Last, Dr. Bjerregaard emphasizes that QTc intervals “as low as 340
o 350 ms. . .have been observed for years without reports of any
ncreased risk for sudden cardiac death.” This comment is rather
aive, as the majority of patients with long-QT syndrome and QTc
ntervals in excess of 480 ms diagnosed later in life have led
symptomatic and prosperous lives. This does not reflect the fact that
significant proportion of patients with long-QT syndrome with
imilar QTc intervals have succumbed to the tragedy of a premature
udden death. In addition, we would reiterate that a diagnosis of
QTS using the diagnostic criteria cannot be made based on a QTc
nterval in isolation and requires the inclusion of relevant clinical and
enetic information.
Despite the negative perspective offered by Dr. Bjerregaard, we
elieve that our diagnostic criteria will allow a thoughtful and
ystematic evaluation of patients potentially harboring the SQTS. The
se of a diagnostic scorecard will assist in bringing uniformity to the
iagnosis of this rare condition, as it has for other conditions, such as
rrhythmogenic right ventricular cardiomyopathy, for which a single
linical test or observation cannot define the disease. Certainly, this
pproach should be favored over personal opinion.
ason D. Roberts, MD
Michael H. Gollob, MD
University of Ottawa Heart Institute
nherited Arrhythmia Clinic and Arrhythmia Research
aboratory
0 Ruskin Street
ttawa, Ontario K1Y 4W7
anada
-mail: mgollob@ottawaheart.cadoi:10.1016/j.jacc.2011.04.019
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Dabigatran in Patients With
Nonvalvular Atrial Fibrillation
In the “2011 ACCF/AHA/HRS Focused Update on the Manage-
ment of Patients With Atrial Fibrillation (Update on Dabigatran)”
(1), the writing committee provides a Class IB recommendation for
abigatran as a useful “alternative to warfarin” in most patients with
onvalvular atrial fibrillation.
The guideline, like the manufacturer’s prescribing information,
mplies that a patient with creatinine clearance 15 to 30 ml/min is a
andidate for dabigatran 75 mg twice daily (bid), despite the fact that
atients with creatinine clearance 30 ml/min were excluded from
he RE-LY trial (2), on which the recommendation is primarily
ased. We do not know, in fact, that dabigatran 75 mg bid is safe in
hese fragile patients or that it is effective in anyone.
How did the 75-mg dose come about? The U.S. Food and Drug
dministration (FDA) Division of Cardiovascular and Renal Prod-
cts explains, but hardly reassures: “Based on pharmacokinetic mod-
ling, comparing pharmacokinetic data from RE-LY with data from
small study of subjects with compromised renal function, a dosing
egimen of 75 mg bid appears appropriate for patients with estimated
rCL 15 to 30 mL/min” (3).
Although it is encouraging that intracranial hemorrhage was less
requent with dabigatran than with warfarin in RE-LY, most sea-
oned clinicians will recall any number of patients who presented with
verwhelming, fatal hemorrhagic diatheses, with or without intracra-
ial hemorrhage, as a result of over-anticoagulation. Compared with
arfarin, dabigatran has the advantage—and the disadvantage—of
ot being subject to periodic monitoring and titration; it is
liminated by an organ whose function routinely varies remarkably
n the elderly, and it has no antidote. As I contemplate using 150
g bid, effectively within a one-size-fits-all paradigm, my concern
s that we may begin to collect more such tragic vignettes.
The “average” patient in RE-LY was 71 years of age, weighed 83
g, and had a creatinine clearance (by the Cockcroft-Gault method)
f 106 ml/min. An 80-year-old woman who weighs 60 kg and has a
erum creatinine level of 1.3 has an estimated creatinine clearance of
3 ml/min. It is generally agreed that formulas for calculating
lomerular filtration rate are fraught with error, but assuming 33
l/min is correct, what dose of dabigatran is right for her? Here is the
DA’s advice: “Patients with CrCL31 mL/min should receive 150
g bid” (3).
It appears that we are to assume that this woman’s risk of serious
leeding with dabigatran 150 mg bid exceeds that of the more robust
average” patient only by a small, clinically acceptable margin, but, in
act, we do not know what that margin is.What is more, although sheualifies for 150 mg bid (according to the manufacturer, the FDA,
nd the new guideline) a week from now, when her serum creatinine
evel chances to be 1.5 and her creatinine clearance 28ml/min, she will
ot qualify. She will instead be relegated to an untested dose that
eemed “appropriate” on pharmacokinetic grounds.
In summary, the recommendation to use dabigatran 75 mg bid in
atients with atrial fibrillation is Class IIb at best, and Level C; there
s no randomized trial. The recommendation for 150 mg bid,
lthough Level B, is Class IIa: “additional studies with focused
bjectives are needed.” The nearly unqualified endorsement of Class I
tatus is not warranted.
Lawrence Gage, MD
Rochester General Hospital
ochester Cardiopulmonary Group, P.C.
445 Portland Avenue, Suite 104
ochester, New York 14621
-mail: lgage@rcpg.com
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Reply
The American College of Cardiology Foundation/American Heart
Association (ACCF/AHA) welcomes letters to inform its ongoing
work and encourages such correspondence about its guidelines.
Because the ACCF/AHA guideline development process is rigorous
and involves several layers of review by the writing committee, external
peer reviewers, and participating organizations in the document, it
cannot respond to each issue raised after a guideline has been
published. The information, however, is forwarded to the Writing
Committee Chair and Oversight Task Force for review. If any issue
is deemed by the ACCF/AHA to affect patient safety, it will be
considered immediately. Otherwise, the information will be consid-
ered during the next update or revision of the guideline.
*Lisa Bradfield
*Science and Quality Division
American College of Cardiology Foundation/
American Heart Association
Heart House
2400 N Street NW, Office 719a
Washington, DC 20037
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